BMCM
TEVA icon

Burns Matteson Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Burns Matteson Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$544K Buy
16,057
+29
+0.2% +$966 0.17% 104
2026
Q1 		$483K Buy
16,028
+7,151
+81% +$230K 0.18% 123
2025
Q4 		$277K Buy
+8,877
New +$219K 0.1% 163

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Burns Matteson Capital Management's TEVA Position: Q2 2026 in Review

Burns Matteson Capital Management increased its Teva Pharmaceuticals (TEVA) stake by 0.18% in Q2 2026, buying an estimated $966 and bringing the position to 16,057 shares worth $544K. The position accounts for 0.17% of the portfolio, ranked #104.

Burns Matteson Capital Management first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Burns Matteson Capital Management held 16,057 shares of Teva Pharmaceuticals worth $544K as of Q2 2026.
  • Burns Matteson Capital Management bought 29 Teva Pharmaceuticals shares in Q2 2026, an estimated $966.
  • Teva Pharmaceuticals made up 0.17% of Burns Matteson Capital Management's portfolio in Q2 2026, its #104 holding.
  • Burns Matteson Capital Management first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Burns Matteson Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.